Rise Advisors LLC Takes $50,000 Position in Boston Scientific Co. (NYSE:BSX)

Rise Advisors LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 731 shares of the medical equipment provider’s stock, valued at approximately $50,000.

A number of other large investors have also recently made changes to their positions in the company. BSW Wealth Partners increased its position in shares of Boston Scientific by 2.3% in the 4th quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock valued at $428,000 after purchasing an additional 165 shares during the last quarter. Allstate Corp increased its holdings in Boston Scientific by 2.9% in the fourth quarter. Allstate Corp now owns 5,938 shares of the medical equipment provider’s stock valued at $343,000 after buying an additional 165 shares during the last quarter. Valley National Advisers Inc. raised its stake in Boston Scientific by 2.3% in the fourth quarter. Valley National Advisers Inc. now owns 7,526 shares of the medical equipment provider’s stock valued at $435,000 after buying an additional 170 shares in the last quarter. Aveo Capital Partners LLC lifted its holdings in Boston Scientific by 1.3% during the 4th quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock worth $742,000 after buying an additional 171 shares during the last quarter. Finally, Whitaker Myers Wealth Managers LTD. boosted its position in shares of Boston Scientific by 4.6% during the 4th quarter. Whitaker Myers Wealth Managers LTD. now owns 4,093 shares of the medical equipment provider’s stock worth $237,000 after acquiring an additional 179 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 0.9 %

NYSE BSX opened at $76.98 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $112.94 billion, a P/E ratio of 64.69, a P/E/G ratio of 2.63 and a beta of 0.81. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $77.64. The firm has a 50-day moving average price of $73.71 and a 200 day moving average price of $66.59.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The business had revenue of $3.86 billion during the quarter, compared to the consensus estimate of $3.68 billion. Equities research analysts expect that Boston Scientific Co. will post 2.32 EPS for the current year.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $69.30, for a total value of $1,133,124.30. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,509,213.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP John Bradley Sorenson sold 16,351 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the sale, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,509,213.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 9,818 shares of Boston Scientific stock in a transaction on Friday, April 26th. The stock was sold at an average price of $73.29, for a total value of $719,561.22. Following the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at $3,032,300.46. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,627 shares of company stock worth $5,937,353. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. Raymond James boosted their target price on Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research note on Thursday, April 25th. Robert W. Baird boosted their price objective on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Royal Bank of Canada increased their target price on shares of Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research report on Thursday, April 25th. Needham & Company LLC reissued a “buy” rating and issued a $82.00 price target on shares of Boston Scientific in a research report on Tuesday. Finally, Mizuho raised their price objective on Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, May 15th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $76.70.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.